ICER Draft Evidence Report on Lykos’ MDMA-Assisted Psychotherapy Deems Clinical Evidence “Insufficient” Post published:March 27, 2024 Post category:Analysis/News/Pα+
Notes from the International Society for Research on Psychedelics’ 2024 Conference in New Orleans (Guest Contribution) Post published:March 20, 2024 Post category:News/Opinions
Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder Post published:March 14, 2024 Post category:Analysis/News/Pα+
Cybin Scores Breakthrough Therapy Designation for Deuterated Psilocybin Analog in MDD, Shares 4-Month Data Post published:March 13, 2024 Post category:Analysis/News/Pα+
FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder; Company Provides 12-Week Data and Fleshes Out Phase 3 Program Plans Post published:March 7, 2024 Post category:Analysis/News/Pα+
Prominent At-Home Ketamine Co. Founder, Juan Pablo Cappello, Sounds Alarm, Withdraws Support for the Practice Post published:March 4, 2024 Post category:Analysis/News/Pα+
Ibogaine Advocates Seek Ohio Opioid Settlement Funds Following Failure in Kentucky Post published:February 23, 2024 Post category:Analysis/News
European Union Grants €6.5M for Multi-Site Psilocybin Study in Palliative Patients Post published:January 24, 2024 Post category:Analysis/News
The Obscure Advisory Panel Blocking Dozens of Psychedelic Studies in California Post published:January 9, 2024 Post category:Analysis/News
MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics Post published:January 5, 2024 Post category:Analysis/News